Bicara Therapeutics Inc.
BCAX
$9.32
-$0.11-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 12.68M | 10.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 56.15M | 46.93M |
| Operating Income | -- | -- | -- | -56.15M | -46.93M |
| Income Before Tax | -- | -- | -- | -62.57M | -56.14M |
| Income Tax Expenses | -- | -- | -- | 6.50K | 6.00K |
| Earnings from Continuing Operations | -- | -- | -- | -62.57 | -56.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -62.57M | -56.14M |
| EBIT | -- | -- | -- | -56.15M | -46.93M |
| EBITDA | -- | -- | -- | -56.11M | -46.90M |
| EPS Basic | -- | -- | -- | -96.01 | -92.21 |
| Normalized Basic EPS | -- | -- | -- | -60.00 | -57.62 |
| EPS Diluted | -- | -- | -- | -96.01 | -92.21 |
| Normalized Diluted EPS | -- | -- | -- | -60.00 | -57.62 |
| Average Basic Shares Outstanding | -- | -- | -- | 2.66M | 2.43M |
| Average Diluted Shares Outstanding | -- | -- | -- | 2.66M | 2.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |